FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells

B. Crescenzi; A. Chase; R. La Starza; D. Beacci; V. Rosti; A. Gallì; G. Specchia; M. F. Martelli; P. Vandenberghe; J. Cools; A. V. Jones; N. C P Cross; P. Marynen; C. Mecucci

doi:10.1038/sj.leu.2404510

FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells

B. Crescenzi, A. Chase, R. La Starza, D. Beacci, V. Rosti, A. Gallì, G. Specchia, M. F. Martelli, P. Vandenberghe, J. Cools, A. V. Jones, N. C P Cross, P. Marynen, C. Mecucci

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article

Abstract

We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib. Fluorescence in situ hybridization specific for BCR-ABL1 and for FIP1L1-PDGFRA was combined with cytomorphology or with lineage-restricted monoclonal antibodies and applied in CML and CEL, respectively. In CEL the amount of FIP1L1-PDGFRA+ cells among CD34+ and CD133+ cells, B and T lymphocytes, and megakaryocytes were within normal ranges. Positivity was found in eosinophils, granulo-monocytes and varying percentages of erythrocytes. In vitro assays with imatinib showed reduced survival of peripheral blood mononuclear cells but no reduction in colony-forming unit growth medium (CFU-GM) growth. In CML the BCR-ABL1 fusion gene was detected in CD34+/CD133+ cells, granulo-monocytes, eosinophils, erythrocytes, megakaryocytes and B-lymphocytes. Growth of both peripheral blood mononuclear cells and CFU-GM was inhibited by imatinib. This study provided evidence for marked differences in the leukemic masses which are targeted by imatinib in CEL or CML, as harboring FIP1L1-PDGFRA or BCR-ABL1.

Original language	English
Pages (from-to)	397-402
Number of pages	6
Journal	Leukemia
Volume	21
Issue number	3
DOIs	https://doi.org/10.1038/sj.leu.2404510
Publication status	Published - Mar 2007

ASJC Scopus subject areas

Hematology
Cancer Research

Access to Document

10.1038/sj.leu.2404510

Fingerprint Dive into the research topics of 'FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells'. Together they form a unique fingerprint.

Cite this

Crescenzi, B., Chase, A., Starza, R. L., Beacci, D., Rosti, V., Gallì, A., Specchia, G., Martelli, M. F., Vandenberghe, P., Cools, J., Jones, A. V., Cross, N. C. P., Marynen, P., & Mecucci, C. (2007). FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Leukemia, 21(3), 397-402. https://doi.org/10.1038/sj.leu.2404510

FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. / Crescenzi, B.; Chase, A.; Starza, R. La; Beacci, D.; Rosti, V.; Gallì, A.; Specchia, G.; Martelli, M. F.; Vandenberghe, P.; Cools, J.; Jones, A. V.; Cross, N. C P; Marynen, P.; Mecucci, C.

In: Leukemia, Vol. 21, No. 3, 03.2007, p. 397-402.

Research output: Contribution to journal › Article

Crescenzi, B, Chase, A, Starza, RL, Beacci, D, Rosti, V, Gallì, A, Specchia, G, Martelli, MF, Vandenberghe, P, Cools, J, Jones, AV, Cross, NCP, Marynen, P & Mecucci, C 2007, 'FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells', Leukemia, vol. 21, no. 3, pp. 397-402. https://doi.org/10.1038/sj.leu.2404510

Crescenzi, B. ; Chase, A. ; Starza, R. La ; Beacci, D. ; Rosti, V. ; Gallì, A. ; Specchia, G. ; Martelli, M. F. ; Vandenberghe, P. ; Cools, J. ; Jones, A. V. ; Cross, N. C P ; Marynen, P. ; Mecucci, C. / FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. In: Leukemia. 2007 ; Vol. 21, No. 3. pp. 397-402.

@article{34a1d889f153492bba4cb9ed5b9cb677,

title = "FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells",

abstract = "We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib. Fluorescence in situ hybridization specific for BCR-ABL1 and for FIP1L1-PDGFRA was combined with cytomorphology or with lineage-restricted monoclonal antibodies and applied in CML and CEL, respectively. In CEL the amount of FIP1L1-PDGFRA+ cells among CD34+ and CD133+ cells, B and T lymphocytes, and megakaryocytes were within normal ranges. Positivity was found in eosinophils, granulo-monocytes and varying percentages of erythrocytes. In vitro assays with imatinib showed reduced survival of peripheral blood mononuclear cells but no reduction in colony-forming unit growth medium (CFU-GM) growth. In CML the BCR-ABL1 fusion gene was detected in CD34+/CD133+ cells, granulo-monocytes, eosinophils, erythrocytes, megakaryocytes and B-lymphocytes. Growth of both peripheral blood mononuclear cells and CFU-GM was inhibited by imatinib. This study provided evidence for marked differences in the leukemic masses which are targeted by imatinib in CEL or CML, as harboring FIP1L1-PDGFRA or BCR-ABL1.",

author = "B. Crescenzi and A. Chase and Starza, {R. La} and D. Beacci and V. Rosti and A. Gall{\`i} and G. Specchia and Martelli, {M. F.} and P. Vandenberghe and J. Cools and Jones, {A. V.} and Cross, {N. C P} and P. Marynen and C. Mecucci",

year = "2007",

month = mar,

doi = "10.1038/sj.leu.2404510",

language = "English",

volume = "21",

pages = "397--402",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells

AU - Crescenzi, B.

AU - Chase, A.

AU - Starza, R. La

AU - Beacci, D.

AU - Rosti, V.

AU - Gallì, A.

AU - Specchia, G.

AU - Martelli, M. F.

AU - Vandenberghe, P.

AU - Cools, J.

AU - Jones, A. V.

AU - Cross, N. C P

AU - Marynen, P.

AU - Mecucci, C.

PY - 2007/3

Y1 - 2007/3

N2 - We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib. Fluorescence in situ hybridization specific for BCR-ABL1 and for FIP1L1-PDGFRA was combined with cytomorphology or with lineage-restricted monoclonal antibodies and applied in CML and CEL, respectively. In CEL the amount of FIP1L1-PDGFRA+ cells among CD34+ and CD133+ cells, B and T lymphocytes, and megakaryocytes were within normal ranges. Positivity was found in eosinophils, granulo-monocytes and varying percentages of erythrocytes. In vitro assays with imatinib showed reduced survival of peripheral blood mononuclear cells but no reduction in colony-forming unit growth medium (CFU-GM) growth. In CML the BCR-ABL1 fusion gene was detected in CD34+/CD133+ cells, granulo-monocytes, eosinophils, erythrocytes, megakaryocytes and B-lymphocytes. Growth of both peripheral blood mononuclear cells and CFU-GM was inhibited by imatinib. This study provided evidence for marked differences in the leukemic masses which are targeted by imatinib in CEL or CML, as harboring FIP1L1-PDGFRA or BCR-ABL1.

AB - We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib. Fluorescence in situ hybridization specific for BCR-ABL1 and for FIP1L1-PDGFRA was combined with cytomorphology or with lineage-restricted monoclonal antibodies and applied in CML and CEL, respectively. In CEL the amount of FIP1L1-PDGFRA+ cells among CD34+ and CD133+ cells, B and T lymphocytes, and megakaryocytes were within normal ranges. Positivity was found in eosinophils, granulo-monocytes and varying percentages of erythrocytes. In vitro assays with imatinib showed reduced survival of peripheral blood mononuclear cells but no reduction in colony-forming unit growth medium (CFU-GM) growth. In CML the BCR-ABL1 fusion gene was detected in CD34+/CD133+ cells, granulo-monocytes, eosinophils, erythrocytes, megakaryocytes and B-lymphocytes. Growth of both peripheral blood mononuclear cells and CFU-GM was inhibited by imatinib. This study provided evidence for marked differences in the leukemic masses which are targeted by imatinib in CEL or CML, as harboring FIP1L1-PDGFRA or BCR-ABL1.

UR - http://www.scopus.com/inward/record.url?scp=33847222196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847222196&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404510

DO - 10.1038/sj.leu.2404510

M3 - Article

C2 - 17215855

AN - SCOPUS:33847222196

VL - 21

SP - 397

EP - 402

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -